MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. Revenue for the year ending December 31, 2023: USD 0.00

MedPacto, Inc. Revenue is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

MedPacto, Inc. Revenue for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
MedPacto, Inc. Revenue for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
MedPacto, Inc. Revenue for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
MedPacto, Inc. Revenue for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years